GSK, Sanofi and Merck Seek Further Inroads In India Industry
This article was originally published in PharmAsia News
Executive Summary
The strictly local pharmaceutical industry in India is expected to shrink this year as at least three companies consider international deals. U.K.-based GlaxoSmithKline is said to be interested in Piramal Healthcare, while Sanofi-Aventis of France and Merck KGaA of Germany consider other ties. GSK already had tipped its hand when it said it was stepping up its focus on emerging markets. Merck said it was interested in signing an Indian deal later this year as it negotiates other local ties, including at least two acquisitions. (Click here for more
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.